上海APASL2017学术之旅中的必到“景点”(15日)
还有五天,第二十六届亚太肝病学会(APASL)年会就要在上海拉开帷幕了。这是一场投稿人数已经破纪录,参会人数必将创下新高的学术饕餮盛宴。是不是有很多医生计划利用会前最后一个双休日好好准备今年的第一场肝病学术的朝圣之旅?那么在收拾行囊的时候,也抽点时间来看看这场学术之旅上都有哪些“景点”是必去的?
当然,如果内容太多,看不过来,就请持续关注《国际肝病》APASL特别报道吧!届时,《国际肝
病》将与大会组委合作,独家推出《每日新闻》(英文),同时我们将从实时微信、网站、会议特刊等多个平台为您呈现“三位一体”的全方位大会盛况。
2月15日星期三会议一句话点评:手拉手,心连心
2月15日的内容由APASL与其他专业学会、组织的联合会议构成,包括APASL与美国肝病研究学会(AASLD)、欧洲肝脏研究学会(EASL)和非政府组织(NGO)。
APASL-NGO联合论坛
该论坛不仅是APASL历史上的首开先河,在国际权威学术会议中也独一无二。论坛以“携手消除亚太地区病毒性肝炎”为主题,从肝病负担、2030年消除肝炎的障碍(社会影响、检测和诊断、治疗、增加治疗可及)以及如何与科研部门合作等几大板块分别展开全体讨论和分组讨论。
APASL-AASLD联合论坛。
本届的APASL-AASLD联合论坛匠心独运,授人以渔,筹备和规划时间超过一年,两个学会的组织者投入了大量心血。论坛针对亚洲国家年的中低年资医生,给他们提供一个与顶尖专家直接交流学习的环境,进行临床研究方法学培训。
据悉,论坛由APASL和AASLD共同资助,从前期投稿中挑选了40名年轻医生,不仅资助其参加APASL2017,还将在联合论坛中分组,由权威专家“开小灶”、针对他们的研究进行指点。
主要内容有临床研究的设计和数据处理,如:
l Refine Question, Aims, Study Design Endpoints of Interventional Trials
Norah TERRAULT, San Francisco
l Operational Issues, Recruitment, Retention, Data Collection, and Monitoring
Lai WEI, Beijing
l Real World Data: Phase 4 studies and Registries
Jia-Horng KAO, Taipei
以及成功发表论文的技巧,如:
l Manuscript Preparation and Submission, Consort Statements and Authorship: ICMJE Guidelines
Henry L.Y. CHAN, Hong Kong
l Response to Reviewers' Comments: Accept, Revise and Reject
Anna S.F. LOK, Ann Arbor
温馨提示下,放心,没投稿或没被选中的一样可以听课学习的。
APASL-EASL联合论坛
欧亚两地的学者将对新登顶的全球第一大肝病“非酒精性脂肪性肝病”的发病机制、组织病理学和管理的进展进行交流和分析。如:
l Genetic and Epigenetic Mechanisms of Nonalcoholic Fatty Liver Disease
Jacob GEORGE, Sydney
l Noninvasive Evaluation of Disease Progression in Nonalcoholic Fatty Liver Disease
Laurent CASTERA, Paris
l Quantitative Assessment of Fibrosis Progression in Liver Histology of Nonalcoholic Steatohepatitis
Yan WANG, Guangzhou
上海APASL2017学术之旅中的必到“景点”(16、17日)
2月16日星期四会议一句话点评:生有涯而知也无涯。
本日的议程表面很简单,内容可谓博大精深。这一天的主要内容有:APASL与WHO和国际腹水俱乐部(IAC)分别联合举办的两个论坛以及三场继续教育课程。
继续教育课程:阻止患者进展到共同结局:肝硬化2017
课程分为四大部分:①理解肝硬化的最新概念;②从病因治疗角度预防肝硬化;③多学科协作管理门静脉高压:新技术、新方法;④肝硬化并发症管理的专家意见。
精彩报告如:
l Evaluation and Staging of Liver Fibrosis: Performance and Standardization
Guiqiang WANG, Beijing
l Management of Liver Fibrosis: APASL Recommendations
Gamal SHIHA, Cairo
l Reversal of Liver Fibrosis and Cirrhosis after Long-term Antiviral Treatment for Chronic Hepatitis B
Teerha PIRATVISUTH, Hat Yai
l Long Term Outcome after Clearing the Virus of HCV
Norah TERRAULT, San Francisco
l Novel Targets and Therapies for the Management of Portal Hypertension
Guadalupe GARCIA-TSAO, New Haven
l Surgical Management of Portal Hypertension
Xiaoping CHEN, Wuhan
l Treatment of Ascites: Drugs, Decompression or Device?
Virendra SINGH, Chandigarh
基础科学课程:肝脏学领域的医学进展和影响
课程分为:①研究前沿:肝脏和炎症;②突出进展:胆汁、脂肪和铁在肝脏的沉积;③阻断肝病进展、修复、缓解、重建;④新靶点、新疗法。
精彩报告如:
l Virology in Viral Hepatitis B
Ulrike PROTZER, Munich
l Metabolism and Inflammation in Fatty Liver
Jacob GEORGE, Sydney
l Fibrogenesis - Discoveries to Repair the Liver Cells
Detlef SCHUPPAN, Mainz
l Validated and Potential Novel Targets to Treat Hepatitis B
Fabien ZOULIM, Lyon
肝移植课程:多学科团队协作模式
课程分为:①肝移植的选择;②肝移植中心——2017年的发展趋势和挑战;③肝移植患者的多学科管理;④先进技术和展望。
精彩报告如:
l New Options and New Possibilities for Liver Transplantation in Acute-on-chronic Liver Failure
Roger S. WILLIAMS, London
l Immune Tolerance and Rejection
Sandy FENG, San Francisco
l DCD Donor System in China: Progress and Challenge
Feng HUO, Guangzhou
APASL-WHO联合论坛
三大板块:①2030年消除病毒性肝炎:国家措施;②2017WHO指南肝炎检测的开展及检测方式区域创新;③消除乙肝在亚洲的母婴传播。特别值得关注的是,论坛上将会发布WHO有关中低收入国家肝炎检测的建议、服务提供模式与实施指南,以及我国开展的“小贝壳”母婴阻断工程的介绍。
精彩报告如:
l Australia: Early Success Towards Elimination
Stephen A. LOCARNINI, Melbourne
l China: National Action Towards Elimination of Viral Hepatitis
Xiaochun WANG, Beijing
l WHO Guidelines on Hepatitis Testing in Low And Middle Income Countries: Recommendations, Service Delivery Models and Implementation
Philippa EASTERBROOK, Geneva
l Towards Zero Transmission of HBV from Mother-to-child: SHIELD Project
Zhihua LIU, Guangzhou
上海APASL2017学术之旅中的必到“景点”(17日)
2月17日,星期五,会议内容一句话点评:开幕了,大咖云集的一天
APASL2017的开幕式将在2月17日的上午8点举行。随后就将迎来本届会议的一个高潮——主席演讲和三场State-of-Art lecture演讲。接下来就是各细分领域的平行会议,转化医学课程,以及专题合作小组会议(SNG)。此外,最能反映一个会议学术水平的环节,最新研究成果的展示将陆续以大会报告、口头汇报、Late Breaking报告、青年研究者汇报和壁报等形式从今天陆续展开。最后,晚上举办的Culture Night也不要错过哦。
精彩报告如:
主席演讲
Clinical Network for Hepatitis B Cure and the Prevention of Mother-infant Transmission
Jinlin HOU, Guangzhou
State-of-Art lecture演讲
01: Decision-Making in Hepatitis B: Integrating Guidelines, Research Data and Clinical Setting
Anna S.F. LOK, Ann Arbor
02:Microbiota and the Liver
Lanjuan LI, Hangzhou
03:Novel Approches and Therapeutics in Acute on Chronic Liver Failure
Shiv K. SARIN, New Delhi
Late Breaking报告
LB001 Hepatitis B Virologic Response and Resistance to Two Antiviral Therapy Regimens Among Hiv and Hbv Co-Infected Pregnant Women: Data from A Phase Ii Randomized Controlled Trial in Guangxi, China
LB002 Tenofovir Mono Rescue Therapy is Effective for Chronic Hepatitis B Patients with Multiple Nucleos(T)Ides Treatment Failure
LB003 Dual Mechanism of Actions of Novel Hbv Core Protein Allosteric Modifiers (Cpams): Inhibiting Viral Replication and Blocking cccDNA Formation
LB004 Correlation between Serum Hbv Rna , Hbv Dna, Hbsag, Hbeag and Lntrahepatic Cccdna at Baseline and 96 Weeks after Nucleos(T)Ide Analogues Treatment in Hbeag-Positive Patients with Chronic Hbv Infection
LB005 A Phase 3 Evaluation of Daclatasvir Plus Asunaprevir In Treatment-Naive Patients with Chronic HCV Genotype 1B Infection
LB006 Sustained Virological Response in Hcv Patients Treated with Daclatasvir + Sofosbuvir, With or Without Ribavirin: A Multicenter, Field-Practice Experience
LB007 Everest: Twelve-week Treatment Of Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin without Interferon Produces 100% SVR 12 in Treatment-Naive Chinese HCV Genotype 1 Patients without Cirrhosis
LB008 Relapse of Minimal Gepatic Encephalopathy After Treatment In Patients With Liver cirrhosis
LB009 Prevalence Of Pre-Treatment Ns5a And Ns5b Ni Resistance Associated Substitutions In HCV Infected Patients Enrolled In Clinical Trials In Asia
大会报告01
PL001 Impact of Baseline NS5A Polymorphisms on Sustained Virologic Response Rates to Treatment With Daclatasvir Plus Sofosbuvir with or without Ribavirin in Patients Infected with HCV Genotypes Prevalent in Asia
PL002 Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates with A Favorable Safety Profile in Asian Patients: An Integrated Subgroup Analysis of The ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies
PL003 Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients with Mild or Moderate Renal Impairment
PL004 High Efficacy in Patients with Chronic Hepatitis C Virus (HCV) Genotype (GT)1b Infection Treated with Elbasvir/Grazoprevir (EBR/GZR) for 12 Weeks: An Integrated Analysis
PL005 ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection - A Randomized, Double-Blind, Placebo-Controlled Study
PL006 Statin Use Correlates with Reduced Risk of Pyogenic Liver Abscess: A Population- Based Case-Control Study
平行会议1:乙肝病毒诊断和治疗检测的生物标志物
平行会议2:肝衰竭:直接和具体的管理
平行会议3:炎症、微环境与肿瘤的发展
平行会议4:乙肝管理现状:未满足的需求和障碍
平行会议5:肝纤维化的分子机制:诊断和治疗
平行会议6:肿瘤干细胞与肝细胞癌
转化医学课程1:非病毒性肝炎
转化医学课程2:HCV——理想的丙型肝炎治疗方案
专题合作小组会议(SNG)1: 肝脏疾病的细胞免疫治疗
专题合作小组会议(SNG)2. 药物性肝损伤和肝脏的保护
专题合作小组会议(SNG)3. 肝脏病遗传学新方向
专题合作小组会议(SNG)4. 门静脉高压诊疗新技术
上海APASL2017学术之旅中的必到“景点”(18日)
2月18日星期六,会议内容一句话点评:风景这边独好
作为正式会议的第二天,18日的学术内容和会议形式更为丰富多彩。尤其值得一提的是,这天上午7点半,将对15日举办的APASL-NGO联合论坛讨论内容和结果进行汇报。而6场State-of-Art lecture演讲,必将令参会者大开眼界。此外,在早餐时段的生物医学论坛和3场小型辩论会中,大家将与专家近距离接触,轻松讨论,启发思路。
精彩议题如:
State-of-Art lecture演讲:
04 Hepatitis C: What Next after the Discovery of DAAs
T. Jake LIANG, Bethesda
05 Algorithm for Approach and Management of Sepsis
Rajiv JALAN, London
06 Staging and Treatment Algorithm: APASL Guidelines for HCC
Masao OMATA, Tokyo
07 Clinical and Pre-Clinical New Targets for Fatty Liver
Arun J. SANYAL, Richmond
08 Novel Concept: Integrative Medicine in Liver Disease
Daiming FAN, Xi'an
09 HBV Reactivation
George K.K. LAU, Hong Kong SAR
Late Breaking报告
LB010 Makalu: Twelve-Week of Treatment with Ritonavir-Boosted Danoprevir plus Peginterferon and Ribavirin Produces 96% SVR12 in HCV Genotype 1-Infected Non-Cirrhotic Chinese Patients
LB011 Pre-activation with TLR7 Agonist Accelerates Hepatitis B Virus Clearance in the Mouse Model
LB012 Augmenter of Liver Regeneration Protects Against Carbon Tetrachloride- Induced Liver Injury by Promoting Autophagy in Mice
LB013 First-in-Human Experience with LJN452, an Orally Available Non-bile Acid FXR Agonist, Demonstrates Potent Activation of FXR in Healthy Subjects
LB014 Identification of Clinical Factors and Metabolic Profiling of Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at Risk of Developing Advanced Fibrosis in a Wellness Clinic
LB015 Chronic Hepatitis B Patients Have Increasing Prevalence and Incidence of Chronic Kidney Disease Compared to Matched Non-Chronic Hepatitis B Controls: Results of a Real-World Analysis of 165,594 Patients in the United States
LB016 Increasing Trends in Liver Complications and Non-liver Co-morbidities in Chronic Hepatitis B (CHB) Patients over the Last 15 Years: a Multicenter University and Community-based Study in the United States (U.S.)
LB017 Increasing Age and Comorbidities of Chronic Hepatitis B Patients in the U.S.: A Longitudinal Analysis of a Diverse U.S. Population-Based Cohort of 44,026 CHB Patients Over 10 Years
LB018 Risk of Hepatocellular Carcinoma In Patients With Chronic HBV Infection on Nucleoside/Nucleotide Analog Therapy: A Result of 10-Year Follow up
大会报告02
PL007 Incidence and Risk Prediction of Hepatocellular Carcinoma: Retrospective Analysis of the S-Collate Study
PL008 Effectiveness of Peginterferon Alfa-2a (40KD) Therapy in HBeAg-Positive Chinese Patients with Chronic Hepatitis B at 3 Years Post-Treatment: Sub-Analysis of the Prospective, Global, Observational S-Collate Study
PL009 IL-21 enhances antiviral effect of HBV specific CD8+T cells and promotes anti-HBs generation in chronic HBV infection
PL010 Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Monotherapy for Entecavir-Resistant Chronic Hepatitis B
PL011 Serum HBV RNA Can Reflect the Activity of Intrahepatic cccDNA
PL012 Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Al-3778, A First-In- Class, HBV Core Assembly Modulator Alone and in Combination with Peginterferon- Alpha 2A, in Treatment Naive Hbeag-Positive Chronic Hepatitis B Patients
平行会议7:亚洲丙肝管理:今天与明天
平行会议8:遗传性肝病的临床管理知识
平行会议9:当前肝细胞癌治疗的临床实践:考虑因素及根据
平行会议10:丙肝未解决问题的科学与技术
平行会议11:自身免疫性肝病的临床管理知识
平行会议12:肝癌的新概念与治疗
转化医学课程 3:脂肪肝——分子靶点及治疗策略
转化医学课程 4:肝脏纤维化——从实验研究到治疗
转化医学课程 5
转化医学课程 6
专题合作小组会议(SNG)5:中草药在肝脏疾病管理中的价值
专题合作小组会议(SNG)6:细胞外囊泡在肝脏生物学中的研究
专题合作小组会议(SNG)7:生物样本库
专题合作小组会议(SNG)8:儿童肝脏病学
上海APASL2017学术之旅中的必到“景点”(19日)
2月19日星期天,会议一句话点评:精彩不停歇
APASL2017正式会议最后一天,继续前一天的形式编排和精彩程度。整个议程从3场早间会议辩论开始,它们分别有关HBV功能性治愈生物标志物、门静脉高压的评估,以及伴门静脉癌栓的肝细胞癌。随后仍然有6场State-of-Art lecture演讲满足参会者求知若渴的心情。平行会议、转化医学课程、专题合作小组会议……以及闭幕式,一个都不能少。
精彩报告如:
State-of-Art lecture演讲
10:Noninvasive Evaluation and Staging of Liver Fibrosis: Present and Future
Laurent CASTERA, Paris
11:Novel Markers for Early Diagnosis and Treatment Target of HCC
Hongyang WANG, Shanghai
12:The Definition of HBV Cure and Treatment Endpoints Jia-Horng KAO, Taipei
13:The Coming New Drug and Immunotherapy for HCC: Learning from the Success and Failur
Jordi BRUIX, Barcelona
14:Immunotherapy for Chronic Hepatitis B
Fusheng WANG, Beijing
15:Autoimmune Liver Disease: West vs East
Jidong JIA, Beijing
大会报告03:
PL013 Genome-wide Association Studies Identify Prkcb as A Novel Genetic Susceptibility Locus for Primary Biliary Cholangitis in the Japanese Population
PL014 Ivabradine in Combination with Carvedilol Improves Left Ventricular Diastolic Dysfunction, Clinical Progression and Survival in Cirrhosis- A Prospective Randomized Controlled Trial
PL015 Efficacy and Safety of Regorafenib (REG) versus Placebo (PBO) in Chinese Patients with Hepatocellular Carcinoma (HCC) Progressing on Sorafenib (SOR): Subgroup Analysis of the International, Randomized Phase 3 RESORCE Trial
PL016 Ecto-nucleoside Triphosphate Diphosphohydrolase 3 (NTPDase3) Modulates Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
PL017 Cenicriviroc Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis with Liver Fibrosis: Results from the Year 1 Primary Analysis of the Phase 2b CENTAUR Study
PL018 Prevalence of Metabolic Syndrome and Long-Term Disease Progression in Chronic Hepatitis B Patients with Comorbid Nonalcoholic Fatty Liver Disease
平行会议13:病毒性肝炎与共同感染
平行会议14:脂肪肝的全球化:亚太地区的非酒精性脂肪性肝病
平行会议15:亚洲肝细胞癌的发展趋势及挑战
转化医学课程5:肝癌--肝细胞癌信号转导
转化医学课程6:HBV——直接抗病毒药物的概念与研发
转化医学课程7:HBV——宿主靶向药物的概念与研发
专题合作小组会议(SNG)9:动物模型
专题合作小组会议(SNG)10:有创和无创肝纤维化评估的前沿资讯